Analysis of neutralizing antibodies as well as cellular immune responses in myeloma patients following booster SARS-CoV-2 mRNA vaccines revealed impaired induction of variant neutralization and CD8 T-cell responses. Patients who developed breakthrough infections after booster vaccines had lower levels of live-virus neutralizing antibodies. These data illustrate current challenges with achieving protective immunity to SARS-CoV-2 in these immunocompromised patients and suggest that they should be prioritized for emerging approaches targeting variant-specific immunity.

See article, p. 106.

Clinical use and testing of anti-BCMA chimeric antigen receptor (CAR) T cells for the treatment of multiple myeloma (MM) has so far been restricted to advanced relapsed or refractory patients who progress following multiple prior therapies. To test whether CAR T-cell therapy is a feasible strategy as an early-line therapy while disease burden is low to potentially reduce incidence of immune-related adverse effects, Garfall et al. conducted a phase I clinical trial coadministering anti-BCMA...

You do not currently have access to this content.